Skip to main content

Table 2 Classification of basal-like breast cancer cases using data from central immunohistochemistry assays in the AMBER consortium

From: Frequency of breast cancer subtypes among African American women in the AMBER consortium

IHC-based basal-like classification scheme

Number (percentage) of PAM50 basal-like tumors identified by IHC

Number (percentage) of unclassified (i.e. triple negative, non-PAM50 basal-like)c

Sensitivity for PAM50 subtype

Specificity for PAM50 subtype

Accuracy for PAM50 subtype

HR-, HER2-

174 (84)

-

84%

90%

88%

HR-, HER2-, (EGFR+ or CK5/6+)a

173 (83)

3 (1.4)

83%

91%

88%

HR-, HER2-, CK5/6+b

110 (53)

86 (41)

53%

96%

81%

  1. IHC immunohistochemistry, HR hormone receptor, HER2 human epidermal growth factor receptor 2, EGFR epidermal growth factor receptor, CK5/6 cytokeratin 5/6, PAM50 prediction analysis of microarray 50
  2. aEGFR+ and CK5/6+ defined as ≥ 1% staining in any core
  3. bCK5/6+ defined as a weighted average ≥2% across all cores for a given case
  4. cOf 210 IHC-based triple negative cases with PAM50 subtype
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us